- Home
- PLUT vs BNR Comparison
PLUT vs BNR Comparison
Compare PLUT & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUT
- BNR
- Stock Information
- Founded
- PLUT 2018
- BNR 2014
- Country
- PLUT Hong Kong
- BNR China
- Employees
- PLUT N/A
- BNR N/A
- Industry
- PLUT
- BNR Medical Specialities
- Sector
- PLUT
- BNR Health Care
- Exchange
- PLUT NYSE
- BNR Nasdaq
- Market Cap
- PLUT 34.1M
- BNR 38.3M
- IPO Year
- PLUT 2025
- BNR 2020
- Fundamental
- Price
- PLUT $2.98
- BNR $6.80
- Analyst Decision
- PLUT
- BNR
- Analyst Count
- PLUT 0
- BNR 0
- Target Price
- PLUT N/A
- BNR N/A
- AVG Volume (30 Days)
- PLUT 67.6K
- BNR 52.8K
- Earning Date
- PLUT 01-01-0001
- BNR 08-21-2025
- Dividend Yield
- PLUT N/A
- BNR N/A
- EPS Growth
- PLUT N/A
- BNR N/A
- EPS
- PLUT N/A
- BNR N/A
- Revenue
- PLUT $1,408,881.00
- BNR $72,112,038.00
- Revenue This Year
- PLUT N/A
- BNR $136.32
- Revenue Next Year
- PLUT N/A
- BNR N/A
- P/E Ratio
- PLUT N/A
- BNR N/A
- Revenue Growth
- PLUT 19.61
- BNR 0.53
- 52 Week Low
- PLUT $2.04
- BNR $2.18
- 52 Week High
- PLUT $4.22
- BNR $9.48
- Technical
- Relative Strength Index (RSI)
- PLUT N/A
- BNR 67.23
- Support Level
- PLUT N/A
- BNR $4.47
- Resistance Level
- PLUT N/A
- BNR $9.48
- Average True Range (ATR)
- PLUT 0.00
- BNR 0.74
- MACD
- PLUT 0.00
- BNR 0.36
- Stochastic Oscillator
- PLUT 0.00
- BNR 55.11
About PLUT PLUTUS FINANCIAL GROUP LIMITED
Plutus Financial Group Ltd provides financial services. The company has two reportable segments: securities related services and asset management services. The securities related services segment generated commission by offering securities dealing and brokerage services, securities underwriting and placing services, and other financing services. The asset management services segment generated asset management fee by providing asset management services and investment advisory services.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.